Both animal and human studies demonstrate that LPS stimulate GLP-1 release via Toll-like receptors (TLRs)
These effects are mediated through GLP-1 receptors (GLP-1R), which are widely distributed throughout the body, including the pancreas, liver, skeletal muscle, gastrointestinal tract, cardiovascular system, and central nervous system
J.BecherT.El-HagO.KnospeS.GkeB.FischerU
Together they provide different anti-nausea mechanisms (ginger affects serotonin receptors, peppermint relaxes stomach muscles)
ContinuEM offers proven GLP-1 medications, Semaglutide and Tirzepatide, in our Lakewood clinic, supported by board-certified providers committed to your success
The proportion of patients achieving NASH resolution in the absence of fibrosis progression was 40%, 36%, and 59% for the 0.1, 0.2, and 0.4 mg semaglutide arms, respectively, whereas the corresponding rate in the placebo arm was 17% ( Notably, based on the results from part 1 of the ESSENCE trial, on 15 August 2025, the FDA approved semaglutide 2.4 mg for the treatment of adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
